Pharma · CROs · Healthcare institutions · Researchers

Every clinical trial carries a degree of uncertainty.

Conecsio helps reduce it by giving teams the right data, at the right time, to make better decisions and run their studies.

Data. Trials. Sites. Consent. At every stage, better decisions.

Explore our solutions

At every stage of the trial

Three questions to reduce uncertainty.

01
Health data

Do we have the right data to answer the research question and design the study?

Secondary use of health data for research.
Dataloom →
02
Clinical trials

Which trials should be considered for a patient, and which sites for a study?
Screenact →
03
Consent

How do we inform patients, then obtain and track their consent?
Edop →

Secondary use of health data

Dataloom: Find and qualify the data your study needs.

A source can look relevant and still be unable to answer your research question. Population covered, available variables, clinical depth, longitudinal follow-up, completeness, reuse conditions: you need to know what it actually contains.

Dataloom qualifies your need and identifies the sources to consider, with the information you need to decide which ones to explore further.

Individual-level data stays with its holders.

Representation of the Dataloom experience · fictitious data

Your need
→
Dataloom qualification
→
Sources to consider

Your need

ConditionMetastatic NSCLC
PopulationAdults, second line and beyond
VariablesEGFR status, lines of treatment, overall survival
Period2018 – 2025
ScopeFrance + EU

Sources to consider

Academic cohort

NSCLC, second line and beyond

Population: Patients followed at an expert centre declared
Variables: EGFR, lines, overall survival declared
Follow-up: 2018 – 2024 declared
Reuse: Conditions documented declared

Hospital data warehouse

Thoracic oncology

Variables: EGFR, lines declared · overall survival to be qualified
Follow-up: 2019 – 2025 declared

National registry

Thoracic cancers

Variables: EGFR status to be qualified
Follow-up: 2012 – 2025 declared

Discover Dataloom →How can I showcase my data? →

Screenact: Find the right trial for your patient.Find the right sites for your study.

For care teams looking for a trial.For sponsors choosing their sites.

Representation of the Screenact experience, in development · fictitious data · anonymised sites · trial IDs masked

12 matching trialsNSCLC · stage IV · EGFR · after targeted therapy · PS 1

OpenInvestigational treatmentPhase 2

EGFR inhibitor combined with an anti-MET agent after progression on targeted therapy

Non-small cell lung cancer · NCT0•••••71

5 sites · 1 country

Comprehensive cancer centreLyon
University hospitalSaint-Étienne
University hospitalLille
Cancer instituteBordeaux
University hospitalNantes

OpenInvestigational treatmentPhase 3

Anti-TROP2 antibody–drug conjugate in advanced EGFR-mutated NSCLC

Non-small cell lung cancer · NCT0•••••01

12 sites · 6 countries

University hospitalParis
Comprehensive cancer centreVillejuif
University hospitalMarseille
Cancer instituteToulouse
Comprehensive cancer centreLyon
Istituto oncologicoMilan
PoliclinicoRome
Hospital universitarioMadrid
Instituto oncológicoBarcelona
Cancer instituteBrussels
KankerinstituutAmsterdam
TumorzentrumHeidelberg

OpenInvestigational treatmentPhase 2

EGFR-MET bispecific after failure of a tyrosine kinase inhibitor

Non-small cell lung cancer · NCT0•••••38

3 sites · 3 countries

Comprehensive cancer centreVillejuif
UniversitätsklinikumMunich
Istituto oncologicoMilan

OpenInvestigational treatmentPhase 1b

HER3 inhibitor in combination, pretreated metastatic NSCLC

Non-small cell lung cancer · NCT0•••••52

2 sites · 2 countries

University hospitalParis
Instituto oncológicoBarcelona

8 more matching trials in the list.

Awaiting openingOpen

Discover Screenact →

Edop: Informed consent: signed and traceable.

Consent begins with clear, accessible information.

Edop structures the information and the consent process, using your teams' own content.Clearer for participants. More control for teams.

Data hosted in France by a certified HDS health data host. Electronic signature level configurable for each study.

Demonstration — fictitious data

Study CONEC-2026Participant information · version 3

Understanding how the study worksVideo from the study team · 4 min

I have read the information17 September 2026 · 9:04 pm

I sign my consent

Electronic signature · level set for the study

InformInformation sheet and materials provided by the team, by version.
UnderstandThe team's documents and videos, available at the participant's own pace.
ConsentElectronic signature, at the level configured for the study.
ProveSigned version kept, signature time-stamped.

Discover Edop →

Proof and support

France 2030, French National Research Agency

France 2030 Unicancer

Screenact, Unicancer's partner on two France 2030 award-winning projects

ETNA-DCT · LOGIGAN-BOOST · Call for expressions of interest “Evaluating new tools, new uses and new methodological approaches in clinical research”, run by the French National Research Agency (ANR).

Montpellier Méditerranée Métropole and MedVallée

Conecsio, Boost Invest MedVallée award winner

2026 cohort.

Our supporters

Data and compliance

What each solution processes.

The applicable regulatory and governance requirements depend on the solution and how it is used.

Dataloom

Documents health data sources based on descriptions provided by their holders. Individual-level data never passes through Dataloom.

Screenact

Draws on public trial registries and institution reference data. Trials are searched using clinical criteria, without identifying the patient. Eligibility decisions remain clinical.